Even if you are a natural late riser, if you’re ever faced with cancer, it might be time to make an exception. A study of patients receiving immunotherapy for small-cell lung cancer found a remarkably large difference in survival between those treated early and late in the day. The rest of this article is behind a paywall. Please sign in or subscribe to access the full content.

Most people when diagnosed with lung cancer will probably take the first appointment they can get for treatment. However, a new study adds to evidence that a morning next week might be better than tomorrow afternoon.

Researchers from five Chinese institutions compared the outcomes of 397 patients treated with chemotherapy and either atezolizumab or durvalumab. Atezolizumab and durvalumab are both immune checkpoin

See Full Page